Clinical Trials Results - National Cancer Institute

Skip to content

National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -6 of 6 Show results per page	View Search Criteria \| Help With Results


Sort By:	Version:	Format:


1.		Effectiveness, Safety and Immunogenicity of GSK Biologicals' HPV Vaccine GSK580299 Administered in Healthy Adolescents.

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Prevention				Active				12 to 15				Pharmaceutical / Industry				106636 NCT00534638


2.		Evaluate Safety of a Vaccine Against Cervical Cancer (HPV-16/18 L1/AS04) in Healthy Filipino Females Aged 10 Yrs & Above

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Prevention				Active				10 and over				Pharmaceutical / Industry				108160 NCT00730847


3.		Immunogenicity and Safety of GlaxoSmithKline Biologicals' HPV Vaccine 580299 in Healthy Females 10 - 25 Years of Age.

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Biomarker/Laboratory analysis, Prevention				Active				10 to 25				Pharmaceutical / Industry				106069 NCT00481767


4.		Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Prevention				Approved-not yet active				18 and over				Pharmaceutical / Industry				111955 NCT00799825


5.		Safety Study of GSK Biologicals' HPV Vaccine (GSK-580299) in Healthy Female Subjects.

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Prevention				Approved-not yet active				25 and over				Pharmaceutical / Industry				111712 NCT00811798


6.		Safety and Immunogenicity of GlaxoSmithKline Biologicals' HPV Vaccine 580299 in HIV Infected Females

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Prevention				Active				18 to 25				Pharmaceutical / Industry				107863 NCT00586339

Select All on One Page

| | | | | | | |

A Service of the National Cancer Institute